Chelsea Therapeutics Announces FDA Accelerated Approval of NORTHERA (Droxidopa) for the Treatment of Symptomatic NOH

19-02-2014 Business Wire HealthComments (0)

BiotechnologyChelsea TherapeuticsNortheraPharmaceutical

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of NORTHERA (droxidopa).

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top